Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats

European Journal of Pharmacology

Volumn 580, Issue 1-2, 2008, Pages 231-240

  Windt, Willemijn A K M ^a   van Dokkum, Richard P E ^a   Kluppel, C Alex ^a   Jeronimus Stratingh, C Margot ^b   Hut, Florian ^a   de Zeeuw, Dick ^a   Henning, Robert H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

5 6 Nephrectomy; Angiotensin converting enzyme inhibitor; Proteinuria; Renal ACE activity; Therapy response

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD PRESSURE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXCRETION; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; KIDNEY FAILURE; MALE; NEPHRECTOMY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; URINARY EXCRETION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; LISINOPRIL; MALE; NEPHRECTOMY; PEPTIDYL-DIPEPTIDASE A; PROTEINURIA; RATS; RATS, WISTAR;

EID: 37649024724     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.060     Document Type: Article

References (40)

1. Adamczak M., Gross M.L., Amann K., and Ritz E. Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J. Am. Soc. Nephrol. 15 (2004) 3063-3072
2. Amann K., Buzello M., Simonaviciene A., Miltenberger-Miltenyi G., Koch A., Nabokov A., Gross M.L., Gless B., Mall G., and Ritz E. Capillary/myocyte mismatch in the heart in renal failure-a role for erythropoietin?. Nephrol. Dial. Transplant. 15 (2000) 964-969
3. Amann K., Tyralla K., Gross M.L., Schwarz U., Tornig J., Haas C.S., Ritz E., and Mall G. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int. 63 (2003) 1708-1713
4. Apperloo A.J., De Zeeuw D., and De Jong P.E. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int., Suppl. 45 (1994) S174-S178
5. Bos H., Andersen S., Rossing P., De Zeeuw D., Parving H.H., De Jong P.E., and Navis G. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int., Suppl. 75 (2000) S32-S37
6. Bos H., Henning R.H., De Boer E., Tiebosch A.T., De Jong P.E., De Zeeuw D., and Navis G. Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Kidney Int. 61 (2002) 473-480
7. Buter H., Hemmelder M.H., Navis G., De Jong P.E., and De Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol. Dial. Transplant. 13 (1998) 1682-1685
8. Challah M., Villard E., Philippe M., Ribadeau-Dumas A., Giraudeau B., Janiak P., Vilaine J.P., Soubrier F., and Michel J.B. Angiotensin I-converting enzyme genotype influences arterial response to injury in normotensive rats. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 235-243
9. Cushman D.W., and Cheung H.S. Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim. Biophys. Acta 250 (1971) 261-265
10. Derkx F.H., Tan-Tjiong L., Wenting G.J., Boomsma F., Man in 't Veld A.J., and Schalekamp M.A. Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. Hypertension 5 (1983) 244-256
11. Dikow R., Kihm L.P., Zeier M., Kapitza J., Tornig J., Amann K., Tiefenbacher C., and Ritz E. Increased infarct size in uremic rats: reduced ischemia tolerance?. J. Am. Soc. Nephrol. 15 (2004) 1530-1536
12. GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The Lancet 349 (1997) 1857-1863
13. Haas M., Yilmaz N., Schmidt A., Neyer U., Arneitz K., Stummvoll H.K., Wallner M., Auinger M., Arias I., Schneider B., and Mayer G. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian study group of the effects of enalapril treatment in proteinuric renal disease. Kidney Blood Press Res. 21 (1998) 66-69
14. Heeg J.E., de Jong P.E., van der Hem G.K., and de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 36 (1989) 272-279
15. Huang J., Xu Y., Liu F., Gao S., and Guo Q. Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of lisinopril in human plasma. Rapid Commun. Mass Spectrom. 20 (2006) 248-252
16. Johnston K.M., MacLeod B.A., and Walker M.J. Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics. Can. J. Physiol. Pharm. 61 (1983) 1340-1353
17. Kramer A.B., Laverman G.D., van Goor H., and Navis G. Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage. J. Pathol. 201 (2003) 160-167
18. Kramer A.B., Bos H., van Goor H., and Navis G.J. Sodium intake modifies the negative prognostic value of renal damage prior to treatment with ACE inhibitors on proteinuria induced by adriamycin. Nephron Physiol. 103 (2006) 43-52
19. Laverman G.D., Navis G., Henning R.H., de Jong P.E., and de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 62 (2002) 1020-1025
20. Leenen F.H., Skarda V., Yuan B., and White R. Changes in cardiac ANG II postmyocardial infarction in rats: effects of nephrectomy and ACE inhibitors. Am. J. Physiol. 276 (1999) H317-H325
21. Lin J.H., Chen I.W., Ulm E.H., and Duggan D.E. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. Drug Metab. Dispos. 16 (1988) 392-396
22. Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F., Motolese M., Ponticelli C., Ritz E., and Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N. Engl. J. Med. 334 (1996) 939-945
23. Mayer G. ACE genotype and ACE inhibitor response in kidney disease: a perspective. Am. J. Kidney Dis. 40 (2002) 227-235
24. Metzger R., Bohle R.M., Pauls K., Eichner G., Alhenc-Gelas F., Danilov S.M., and Franke F.E. Angiotensin-converting enzyme in non-neoplastic kidney diseases. Kidney Int. 56 (1999) 1442-1454
25. Ocaranza M.P., Piddo A.M., Faundez P., Lavandero S., and Jalil J.E. Angiotensin I-converting enzyme gene polymorphism influences chronic hypertensive response in the rat Goldblatt model. J. Hypertens. 20 (2002) 413-420
26. Raine A.E., Seymour A.M., Roberts A.F., Radda G.K., and Ledingham J.G. Impairment of cardiac function and energetics in experimental renal failure. J. Clin. Invest. 92 (1993) 2934-2940
27. Ranadive S.A., Chen A.X., and Serajuddin A.T.M. Relative lipophilicities and structural pharmacological considerations of various Angiotensin-Converting Enzyme (Ace) inhibitors. Pharm. Res. 9 (1992) 1480-1486
28. Remuzzi A., Benigni A., Malanchini B., Bruzzi I., Foglieni C., and Remuzzi G. ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. Kidney Int. 47 (1995) 1319-1326
29. Remuzzi G., Perico N., Macia M., and Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int., Suppl. (2005) S57-S65
30. Rook M., Lely A.T., Kramer A.B., van Goor H., and Navis G. Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage. Nephrol. Dial. Transplant. 20 (2005) 59-64
31. Rossing K., Schjoedt K.J., Jensen B.R., Boomsma F., and Parving H.H. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 68 (2005) 1190-1198
32. Sadjadi J., Kramer G.L., Yu C.H., Welborn III M.B., and Modrall J.G. Angiotensin II exerts positive feedback on the intrarenal renin-angiotensin system by an angiotensin converting enzyme-dependent mechanism. J. Surg. Res. 129 (2005) 272-277
33. Scharplatz M., Puhan M.A., Steurer J., Perna A., and Bachmann L.M. Does the Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy?-A systematic review. Curr. Control Trials, Cardiovasc. Med. 6 (2005) 16
34. Schmieder R.E., Klingbeil A.U., Fleischmann E.H., Veelken R., and Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J. Am. Soc. Nephrol. 16 (2005) 3038-3045
35. Schoemaker R.G., Debets J.J., Struyker-Boudier H.A., and Smits J.F. Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. J. Mol. Cell. Cardiol. 23 (1991) 187-197
36. Schunkert H., Ingelfinger J.R., Hirsch A.T., Pinto Y., Remme W.J., Jacob H., and Dzau V.J. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ. Res. 72 (1993) 312-318
37. van Dokkum R.P., Ochodnicky P., Henning R.H., Kluppel A.C., Citgez M., and de Zeeuw D. Endothelial function and ace-activity of the healthy kidney predict susceptibility to renal damage in the rat model for renocardial interaction. J. Am. Soc. Nephrol. 14 (2003) 610A
38. van Dokkum R.P., Eijkelkamp W.B., Kluppel A.C., Henning R.H., van Goor H., Citgez M., Windt W.A., van Veldhuisen D.J., de Graeff P.A., and de Zeeuw D. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J. Am. Soc. Nephrol. 15 (2004) 3103-3110
39. Wapstra F.H., van Goor H., Navis G., De Jong P.E., and De Zeeuw D. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin. Sci. (Lond) 90 (1996) 393-401
40. Windt W.A., Eijkelkamp W.B., Henning R.H., Kluppel A.C., de Graeff P.A., Hillege H.L., Schafer S., de Zeeuw D., and van Dokkum R.P. Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone-system intervention. J. Am. Soc. Nephrol 11 (2006) 393-401